{"classes":[{"categories":[{"measurements":[{"comment":"NA indicates that upper limit of CI was not estimable due to insufficient number of participants with events at study closure.","groupId":"OG000","lowerLimit":"1.413","upperLimit":"NA","value":"2.23"},{"comment":"NA indicates that upper limit of CI was not estimable due to insufficient number of participants with events at study closure.","groupId":"OG001","lowerLimit":"1.347","upperLimit":"NA","value":"2.14"},{"comment":"NA indicates that upper limit of CI was not estimable due to insufficient number of participants with events at study closure.","groupId":"OG002","lowerLimit":"1.347","upperLimit":"NA","value":"5.65"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"23"}],"units":"Participants"}],"description":"EFS was defined as the time interval from the date of first study treatment administration to the date of the first of: completion or going off protocol induction/consolidation therapy without CR, relapse from CR, or death due to any cause, whichever occurred first. It was estimated using the Kaplan-Meier method. CI for Kaplan-Meier estimates are calculated with log-log transformation of survival function and methods of Brookmeyer and Crowley.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with B-ALL received isatuximab 20 mg/kg IV infusion QW for 4 weeks during the induction period (i.e., on Days 1, 8, 15, and 22) and Q2W during the consolidation period (i.e., on Days 29, 43, and 57. Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG000","title":"B-cell Acute Lymphoblastic Leukemia (B-ALL)"},{"description":"Participants with T-ALL received isatuximab 20 mg/kg IV infusion QW for 4 weeks during the induction period (i.e., on Days 1, 8, 15, and 22) and Q2W during the consolidation period (i.e., on Days 29, 43, and 57. Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG001","title":"T-cell Acute Lymphoblastic Leukemia (T-ALL)"},{"description":"Participants with AML received isatuximab 20 mg/kg IV infusion on Days 1, 8, and 15 of each Cycle (up to 2 treatment cycles, each cycle 28 days). Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG002","title":"Acute Myeloid Leukemia (AML)"}],"paramType":"MEDIAN","populationDescription":"The evaluable population consisted of evaluable participants from the AT population who received at least 1 full dose of isatuximab in Cycle 1 and who had at least 1 valid response value that was evaluable.","reportingStatus":"POSTED","timeFrame":"From study treatment administration up to the date of first documented disease progression or death due to any cause, a maximum of 45 months","title":"Event-Free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"months"}